A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes

Evaluation of the Counter-Regulatory Response to Hypoglycaemia Following LY2605541 Administration Compared to Insulin Glargine in Patients With Type 1 Diabetes Mellitus

This study has 2 parts. Each participant will receive a daily injection of LY2605541 during one treatment period and a daily injection of insulin glargine during one treatment period. Each treatment period is 2 to 3 weeks and is followed by a procedure to lower blood sugar levels to see how the body recovers after each treatment.

Inclusion Criteria:

• Type 1 diabetic for more than 1 year with glycated hemoglobin (HbA1c) less than 9%
• Otherwise fit and healthy
• Nonsmoker

Exclusion Criteria:

• Taking medication or supplements other than insulin to control diabetes
• Suffered a hypoglycemic event in the last 12 months that required hospitalization or has poor awareness of hypoglycemia